APM
KNTE

Avidity Partners Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Avidity Partners Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,160,000
Closed -$7.25M – 109
2023
Q1 		$7.25M Sell
1,160,000
-52,700
-4% -$321K 0.24% 68
2022
Q4 		$7.4M Buy
1,212,700
+89
+0% +$725 0.16% 63
2022
Q3 		$14.5M Buy
+1,212,611
New +$15.9M 0.29% 62

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Avidity Partners Management's KNTE Position: Q2 2023 in Review

Avidity Partners Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 1,160,000 shares — an estimated $7.25M sold.

Avidity Partners Management first reported a position in KNTE in Q3 2022 and held it in 3 quarters. The position peaked at $14.5M in Q3 2022. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Avidity Partners Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Avidity Partners Management sold 1,160,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $7.25M.
  • Avidity Partners Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Avidity Partners Management's Kinnate Biopharma Inc. Common Stock position peaked at $14.5M in Q3 2022.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.